TOMORROW 5/28 at 10am ET: Barclays Hosted: Go With Your Gut? How to Think About Current & Emerging Agents in IBD as ABBV/JNJ Face Potential Challenges from ABVX/MRK/ROG/SNY

Research evidence excerpt

TOMORROW 5/28 at 10am ET: Barclays Hosted: Go With Your Gut? How to Think About Current & Emerging Agents in IBD as ABBV/JNJ Face Potential Challenges from ABVX/MRK/ROG/SNY

•• Emily Field, CFA, U.S. Biopharmaceuticals

•• James Gordon, EU Pharma, Biotech & Life Sciences

Event Description

We are hosting a KOL call with Dr. Jordan Axelrad, M.D., MPH, Co-Director of the

Inflammatory Bowel Disease (IBD) Center at NYU Langone Health. The focus of our IBD

discussion will be on how to think about the current and evolving treatment paradigm.

Specifically, we expect to discuss how established biologics and small molecules are

currently positioned across ulcerative colitis (UC) and Crohn’s disease (CD), and how

physician prescribing patterns may evolve with the introduction of next-generation

therapies. We will also explore how potential oral options and differentiated mechanisms

of action could drive changes in treatment sequencing, biologic utilization, and overall

market dynamics.

Key topics of discussion will include the following:

•• Benchmarks: Physicians' expectations on key efficacy and / or safety bars in UC

•• TL1a data to date in ulcerative colitis/Crohn's disease: physician perspective on

efficacy, durability, and differentiation versus existing biologics

•• View on TL1a adoption across UC and CD: how physicians may incorporate TL1a

therapies into treatment algorithms and sequencing

•• Competitive dynamics: how TL1a agents may compete with IL-23s, JAK inhibitors, and

emerging oral therapies across indications

•• Oral vs injectable IL-23 agents: physician perspective on efficacy trade-offs, patient

preference, and potential impact on biologic utilization and treatment sequencing

•• ABVX's obefazimod data to date in ulcerative colitis: Physicians' view on obefazimod